ucsf logo

Elias H. Botvinick, MD

Cardiology
Cardiology Parnassus
415-353-2873
Portrait of Elias H. Botvinick
Portrait of Elias H. Botvinick
ucsf logo

Elias H. Botvinick, MD

Cardiology
Cardiology Parnassus
415-353-2873

On this page

About me

Dr. Elias Botvinick is co-director of the laboratory for noninvasive adult cardiology, director of the laboratory for cardiac stress testing and director of cardiovascular nuclear medicine at UCSF Medical Center.

Botvinick's research focuses on improving evaluation and understanding of cardiac disease through the application of noninvasive imaging techniques, including scintigraphy or radionuclide scanning, echocardiography, computed tomography and magnetic resonance imaging. He also is interested in exploring the mechanism, safety and clinical value of exercise and pharmacologic stress-testing methods, particularly as they apply to the diagnosis and risk assessment of coronary artery disease.

Botvinick earned his medical degree from New York University, where he went on to complete his residency in internal medicine. He also completed two fellowships at UCSF, one in cardiovascular disease and another in nuclear medicine.

Education & training

Board certification

  • Cardiovascular Disease, American Board of Internal Med/Cardiovascular Dis
  • Nuclear Medicine, American Board of Nuclear Medicine
  • Internal Medicine, American Board of Internal Medicine

Fellowship

  • Cardiology, UCSF Graduate Medical Education

Residency

  • Internal Medicine, New York University School of Medicine

Degree

  • MD, New York University School of Medicine

My expertise

Locations

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.